LONDON - Cambridge Antibody Technology Group plc is axing the 50 percent contribution it makes to its antibody development and marketing agreement with Amgen Inc. in favor of a deal in which Amgen meets all the costs and, rather than getting a 50 percent share of the profits, CAT receives fees, milestones and royalties.
